Primary Progressive Aphasia Overview

Save information for later
Sign Up

Learn About Primary Progressive Aphasia

What is the definition of Primary Progressive Aphasia?
Primary progressive aphasia (PPA) affects a person's ability to use language to communicate. This includes loss of ability to understand or express speech (aphasia). PPA is a specific type of a more general disease called frontotemporal dementia. PPA can be classified into three distinct types: progressive non-fluent aphasia (PNFA), semantic dementia (SD), and logopenic progressive aphasia (LPA). PPA is caused by a loss of tissue (atrophy) in the area of the brain that is responsible for producing language. In some cases, this loss of tissue is caused by genetic changes (genetic changes or pathogenic variants) in the GRN gene. In these cases, the disease is inherited in an autosomal dominant manner. Diagnosis of PPA is suspected when a doctor observes signs and symptoms such as progressive loss of language abilities. Imaging of the brain can confirm the diagnosis.
What are the alternative names for Primary Progressive Aphasia?
  • Primary progressive aphasia
  • Aphasia, primary progressive
  • PPA
  • Primary progressive aphasia syndrome
Who are the top Primary Progressive Aphasia Local Doctors?
Elite in Primary Progressive Aphasia
Dr. Argye E. Hillis
Neurology
Elite in Primary Progressive Aphasia
Dr. Argye E. Hillis
Neurology

Johns Hopkins University

600 N Wolf St, 
Baltimore, MD 
410-955-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Argye Hillis is a Neurologist in Baltimore, Maryland. Dr. Hillis is rated as an Elite provider by MediFind in the treatment of Primary Progressive Aphasia. Her top areas of expertise are Primary Progressive Aphasia, Stroke, Frontotemporal Dementia, Thrombectomy, and Gastrostomy. Dr. Hillis is currently accepting new patients.

Elite in Primary Progressive Aphasia
Dr. Zachary A. Miller
Neurology
Elite in Primary Progressive Aphasia
Dr. Zachary A. Miller
Neurology

University Of California San Francisco

2330 Post St, 
San Francisco, CA 
415-476-4029
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Zachary Miller is a Neurologist in San Francisco, California. Dr. Miller is rated as an Elite provider by MediFind in the treatment of Primary Progressive Aphasia. His top areas of expertise are Primary Progressive Aphasia, Frontotemporal Dementia, Dementia, and Developmental Reading Disorder.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Primary Progressive Aphasia
Federica Agosta
Elite in Primary Progressive Aphasia
Federica Agosta
Milan, IT 

Federica Agosta practices in Milan, Italy. Ms. Agosta is rated as an Elite expert by MediFind in the treatment of Primary Progressive Aphasia. Her top areas of expertise are Primary Lateral Sclerosis, Primary Progressive Aphasia, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Deep Brain Stimulation, and Thalamotomy.

View All Doctors
What are the latest Primary Progressive Aphasia Clinical Trials?
Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of Oral Verdiperstat (BHV-3241) in Patients With Semantic Variant Primary Progressive Aphasia (svPPA) Due to TDP-43 Pathology
Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of Oral Verdiperstat (BHV-3241) in Patients With Semantic Variant Primary Progressive Aphasia (svPPA) Due to TDP-43 Pathology
Who is this study for: Patients with semantic variant primary progressive aphasia due to TDP-43 pathology
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Drug
Study Drug: Verdiperstat
Study Phase: Phase 1

Summary: The purpose of the study is to test the safety and tolerability of twice daily Verdiperstat in patients with semantic variant primary progressive aphasia (svPPA) due to frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP). Three-fourths of the participants will receive Verdiperstat and one-fourth will receive Placebo during the 24-week treatment duration.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Sequencing and Initiation in Speech Production: Investigating Speech Sequencing in Neurotypical Speakers, Persons Who Stutter, and Persons With Primary Progressive Aphasia
Sequencing and Initiation in Speech Production: Investigating Speech Sequencing in Neurotypical Speakers, Persons Who Stutter, and Persons With Primary Progressive Aphasia
Enrollment Status: Recruiting
Publish Date: September 19, 2025
Intervention Type: Behavioral, Device
Study Phase: Not Applicable

Summary: Persistent developmental stuttering affects more than three million people in the United States, and it can have profound adverse effects on quality of life. Despite its prevalence and negative impact, stuttering has resisted explanation and effective treatment, due in large part to a poor understanding of the neural processing impairments underlying the disorder. The overall goal of this study is...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center